iCRco files for bankruptcy following lawsuit
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen spends big to defeat Proposition 61
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen sells Colorado facility to AstraZeneca for $64.5 million
Thousand Oaks biotech giant Amgen continued its Colorado exit plans recently as it sold a Longmont, Colo., facility to London-based pharmaceutical and biotech company AstraZeneca for $64.5 million. Amgen built the 692,000-square-foot facility in the 1990s to make ingredients for its blockbuster anti-anemia drug Epogen. The site used large vats to produce lines of cell Read More →
Nurses claim labor law violations in suit against Twin Cities Community Hospital
A group of 53 nurses filed claims against Templeton’s Twin Cities Community Hospital for allegedly violating California labor laws, according to a news release from the law firm Baltodano & Baltodano. The claims were filed in private arbitration on Oct. 3 because of the confidentiality provisions in the nurses’ contracts with the hospital, said Lauren Read More →
Amgen partners with Swedish company to develop drugs
Thousand Oaks-based Amgen will pay a Swedish company up to $410 million to help it develop oncology and neuroscience drugs. The companies announced the partnership Oct. 4 and said Nuevolution will use its Chemetics drug discovery platform to discover drugs for Amgen. Nuevolution may receive licensing payments along with development, commercial and milestone payments. It Read More →
Amgen leukemia drug cures 39 percent of treated patients, study finds
Amgen’s new leukemia drug cured 39 percent of pediatric patients who received treatment, the Thousand Oaks company said Oct. 3 after publishing results of a new study in the Journal of Clinical Oncology. Blincyto, which treats a rare form of the disease known as precursor B-cell acute lymphoblastic leukemia, sent 27 patients out of 70 Read More →
FDA gives big win to Amgen in biosimilars race
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
